Patient enrollment in AVP-923 PRIME Study completed

A board to discuss future MS therapies in early stage (Phase I or II) trials.

Patient enrollment in AVP-923 PRIME Study completed

Postby MSUK » Tue Jul 02, 2013 2:21 am

Avanir Pharmaceuticals, Inc. announced completion of patient enrollment in the company's phase II, placebo controlled study testing three doses of AVP-923 for the treatment of central neuropathic pain in multiple sclerosis. Top-line results from this study are expected in the fourth calendar quarter of 2013.

"Final completion of enrollment in PRIME is an important milestone in the AVP-923 development pathway," said Joao Siffert, MD, chief scientific officer at Avanir. "We are looking forward to the results from this study to help guide design of our phase III studies in neuropathic pain......." - Read More -
User avatar
Family Elder
Posts: 2463
Joined: Wed Oct 14, 2009 3:00 pm


Return to Drug Pipeline


  • Related topics
    Last post

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service